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BACKGROUND: Anaplastic lymphoma kinase (ALK) gene rearrangements are oncogenic drivers in non-small-cell lung cancer
(NSCLC). TSR-011 is a dual ALK and tropomyosin-related kinase (TRK) inhibitor, active against ALK inhibitor resistant tumours in
preclinical studies. Here, we report the safety, tolerability and recommended phase 2 dose (RP2D) of TSR-011 in patients with
relapsed or refractory ALK- and TRK-positive advanced cancers.
METHODS: In this sequential, open-label, phase 1 trial (NCT02048488), patients received doses of 30mg, escalated to 480mg every
24 hours (Q24h), followed by an expansion cohort of patients with ALK-positive cancers. The primary objective was to evaluate
safety and tolerability. Secondary objectives included pharmacokinetics.
RESULTS: TSR-011 320- and 480-mg Q24h doses exceeded the maximum tolerated dose. At the RP2D of 40mg every 8 hours (Q8h),
the most common grade 3–4 treatment-emergent adverse events occurred in 3.2–6.5% of patients. Of 14 ALK inhibitor-naive
patients with ALK-positive NSCLC, 6 experienced partial responses and 8 had stable disease.
CONCLUSIONS: At the RP2D (40mg Q8h), TSR-011 demonstrated a favourable safety profile with acceptable QTc changes. Limited
clinical activity was observed. Based on the competitive ALK inhibitor landscape and benefit/risk considerations, further TSR-011
development was discontinued.
CLINICAL TRIAL REGISTRATION NUMBER: NCT02048488.
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BACKGROUND
Constitutive activation of anaplastic lymphoma kinase (ALK)
stemming from ALK rearrangement is a driving event in a portion
of non-small-cell lung cancers (NSCLCs) and several other cancers.
Twenty different ALK fusion partner genes have been reported
across multiple malignancies.1 The uncontrolled activity of ALK
fusion proteins results in oncogenic signalling in several down-
stream pathways that regulate proliferation and malignant
transformation.2,3 The EML4–ALK translocation detected in NSCLC
is a widely recognised ALK fusion gene and is estimated to exist in
5% of all NSCLC cases worldwide.4
ALK inhibitors are highly effective in ALK-positive NSCLC. For
example, crizotinib5 had better response rates than chemother-
apy, with rates of 74% versus 45% and a median progression-free
survival of 10.9 versus 7.0 months, respectively.6
Despite the efficacy of crizotinib, acquired resistance in treated
patients is a major hurdle, with disease progression occurring within
~1 year.6–8 Resistance mutations were identified in 20% of patients
with disease progression while participating in a clinical trial.9
Resistance mechanisms to crizotinib include ALK amplification;
secondary mutations in the ALK kinase domain (e.g. the gatekeeper
mutation); mutations that enhance ALK activation (e.g. the F1174L
mutation); and activation of bypass signalling pathways (e.g.
alterations to EGFR and KIT signalling).10 More potent next-
generation ALK inhibitors (e.g. ceritinib, alectinib, brigatinib and
lorlatinib) were developed to overcome resistance mutations11 and
are approved for advanced ALK-positive NSCLC.
TSR-011 is a potent next-generation ALK inhibitor that also
targets tropomyosin-related kinase (TRK) family members (TrkA,
TrkB and TrkC).12 TRK proteins play a role in the development and
maturation of the central and peripheral nervous system, as well
as in cell survival. TRK fusion proteins are observed in several
cancers, including papillary thyroid carcinoma, colorectal adeno-
carcinoma, human secretory breast carcinoma and glioblastoma.13
TSR-011 has potency at nanomolar concentrations against wild-
type ALK in vitro and in ALK-dependent cellular models, as well as
in ALK-dependent tumour growth inhibitory activity in mouse
models.12,14 In addition, TSR-011 is ~200-fold more potent than
crizotinib against the L1196M ALK gatekeeper mutant form and is
also about 10-fold more potent than crizotinib against the R1275Q
mutant,14 which is one of the most common activating mutations
in neuroblastoma.15
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This study evaluated the safety, tolerability and pharmacoki-
netic (PK) profile of TSR-011 in relapsed or refractory locally
advanced or metastatic cancer, or cancer for which standard
therapy was unavailable.
METHODS
Study design and treatments
This sequential, open-label, nonrandomised, dose-escalation,
phase 1 clinical trial (ClinicalTrials.gov identifier: NCT02048488)
evaluated the safety and tolerability of TSR-011 immediate-release
(IR) formulation in patients with relapsed or refractory locally
advanced or metastatic cancer, or cancer for which standard
therapy was unavailable. The study was conducted at 15 sites in
Poland, Spain, Taiwan, the United States and the United Kingdom.
A formulation sub-study was also undertaken to evaluate a
controlled-release (CR) formulation of TSR-011 in a similar patient
population.
The primary objective of this trial was to determine the dose-
limiting toxicity (DLT), maximum tolerated dose (MTD) and
recommended phase 2 dose (RP2D) of TSR-011 based on safety,
tolerability, PK and exposure–response analyses.
Endpoints included the incidence of DLTs (defined in the
‘Safety' section) in the first 28-day treatment cycle (cycle 1), the
frequency and severity of adverse events (AEs) and serious AEs
(SAEs) and changes in laboratory values, vital signs, physical
examination findings and Eastern Cooperative Oncology Group
(ECOG) performance status (PS). Plasma concentration and PK
parameters for TSR-011 were also investigated.
The starting dose was 30 mg, which was determined by review
of nonclinical toxicokinetic assessments. A treatment cycle
comprised 28 days in the absence of disease progression or
unacceptable toxicity. Patients received starting doses ranging
from 30mg once every 24 hours (Q24h) to 480mg Q24h, and
escalation proceeded based on a 3+ 3 design.
The occurrence of DLTs in > 1 of six patients in a specific dosage
cohort (or at a rate of ≥ 33% if > 6 patients were in a cohort)
indicated that the MTD had been exceeded. The subsequent
cohort started at a reduced dosing regimen. Additional dosing
schedules were once every 12 hours (Q12h) at 30 and 60mg and
once every 8 hours (Q8h) at 20 and 40mg.
At the end of each 28-day treatment cycle, individual patients
within a cohort were eligible for dose escalation (if other criteria
were met and judged by the investigator to be medically
indicated). Cohort expansion in the case of > 1 DLT was
considered if the DLT could reasonably be considered idiopathic
or related to disease progression.
A phase 2a study of the TSR-011 IR formulation was planned to
treat ALK-positive tumours; however, the study was not initiated
when the sponsor terminated further development of TSR-011.
Patients
Eligible patients were aged ≥ 18 years (except in countries where
the age of majority is 16 years; e.g. the United Kingdom) and had
metastatic or locally advanced solid tumours that did not
respond to standard therapy or progressed, despite standard
therapy, and had either refused standard therapy or standard
therapy was unavailable. Patients had an estimated life expec-
tancy of ≥ 3 months and adequate organ function. In addition,
patients had an ECOG PS ≤ 2. Patients were not required to have
measurable disease.
Patients who were pregnant or had leukaemia or uncontrolled
congestive heart failure were excluded from the study. A protocol
amendment that was implemented before patient enrolment
expanded the exclusion criteria to include patients with ongoing
cardiac dysrhythmias of National Cancer Institute (NCI) Common
Terminology Criteria for Adverse Events (CTCAE) grade ≥ 2, atrial
fibrillation of any grade, corrected QT interval (QTc) > 450ms or
risk factors for torsade de pointes and those receiving QTc-
prolonging medicines. In addition, patients had to stop taking
prescription, over the counter, or herbal medications known to be
inhibitors or inducers of cytochrome P450 (CYP) 3A4 or 3A5.
Further, a protocol amendment was made that required
patients (excluding those in the formulation sub-study) to
demonstrate that they had ALK- or TRK-positive tumours before
enrolment. Mutation status was determined by immunohisto-
chemistry, determination of gene mutations or amplification or
analysis of gene rearrangements by fluorescence in situ hybridisa-
tion. These assays were performed at local laboratories. A total of
52 patients were enrolled after the protocol amendment
implementation (30-mg IR Q12h cohort, n= 5; 20-mg IR Q8h
cohort, n= 16; 40-mg IR Q8h cohort, n= 31).
This clinical investigation was conducted in compliance with
Good Clinical Practice, the Declaration of Helsinki (version 2008)
and other applicable regulatory requirements. The protocol was
approved by the Institutional Review Board at each participating
site, and all patients provided written informed consent before
study participation.
PK analysis
To evaluate PK and establish the RP2D, blood samples were
collected from all patients in the phase 1 dose-escalation trial at
daily doses of 30–480 mg.
A liquid chromatography–tandem mass spectrometry (LC–MS/
MS) method (API 5500, Applied Biosystems, Waltham, MA, USA)
using a Gemini C18 column (Phenomenex, Torrance, CA, USA;
50 × 2.0 mm, 3 µm) for the analysis of TSR-011 in K2EDTA human
plasma was developed and fully validated by Agilux Laboratories
(Worcester, MA, USA). Plasma samples were processed through a
Biotage (Uppsala, Sweden) ISOLUTE SLE+ 200 μL of a 96-well-
supported liquid extraction plate. TSR-011 was determined
using electrospray ionisation in positive ion mode, with the
multiple reaction monitoring transitions of 578/435 for TSR-011
and 596/453 for TSR-012 as its internal standard. The validated
range was 0.87–433.25 nmol/L. The assay interbatch precision,
expressed as percent coefficients of variation, ranged from 6.6 to
11.7%, and the interbatch accuracy, expressed as percent bias,
ranged from –4.7 to 0.5%.
PK parameters were calculated using noncompartmental
analysis (Phoenix WinNonlin version 7.0, Pharsight Corporation,
Mountain View, CA, USA).
Safety
The safety and tolerability of TSR-011 were assessed by evaluating
vital signs, physical examination findings, ECOG PS, clinical
laboratory testing (serum chemistry, haematology and urinalysis),
12-lead electrocardiograms (ECGs), AEs and visual history.
Toxicities were graded and recorded according to NCI CTCAE
version 4.03. Patients were assessed for DLTs during the first 28-
day cycle. A DLT was defined as any grade ≥ 3 nonhaematologic
toxicity, according to NCI CTCAE version 4.03.
Clinical activity
The overall tumour response in all patients with measurable
disease was evaluated, using Response Evaluation Criteria in Solid
Tumors, version 1.1,16 completed at times of radiologic assess-
ment at weeks 4 and 8 after dosing and every 8 weeks thereafter.
For patients without measurable disease at study entry, radiologic
assessment was done as per investigator discretion.
QTc assessments
We assessed potential effects of TSR-011 with the hERG (KIr)
in vitro test system. Inhibition of TSR-011 hERG, via displacement
of dofetilide binding, exhibited a half-maximal inhibitory concen-
tration (IC50) of 2.3 µM. A functional assay evaluating TSR-011
confirmed inhibition of the hERG channel, with an IC50 value of
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0.172 µM. Evaluation of TSR-011 activity against hNav1.5
expressed in HEK-293 cells resulted in an IC50 of 7.6 μM, and a
functional patch-clamp test indicated that the IC50 for calcium
channel inhibition was > 10 μM.
Potential in vivo effects on the respiratory, central nervous and
cardiovascular systems were evaluated in oral dose studies in rats
and dogs. A telemetered dog cardiovascular study performed with
oral doses of 3, 10 and 15mg/kg showed a dose-dependent
prolongation of the PR interval, a small and dose-dependent
increase in QRS duration at 10 and 15mg/kg and prolonged QTc
at ≥ 3mg/kg. Increased heart rate was noted at ≥ 3mg/kg,
decreased pulse pressure at ≥ 10mg/kg and a mild and transient
increase in body temperature at 15 mg/kg. All cardiovascular
parameters returned to normal by the subsequent dose,
indicating reversibility. TSR-011 did not exhibit any effects in a
combined modified Irwin and respiratory safety study in rats at
oral doses ≤ 60mg/kg.
During the phase 1 trial, all patients were monitored by ECGs as
part of safety evaluations. The effect of TSR-011 on ECG
parameters was evaluated following International Council for
Harmonisation of Technical Requirements for Pharmaceuticals for
Human Use E14 guidelines. Cardiac function (QT, Bazett-corrected
QT formula, Fridericia-corrected QT formula [QTcF], PR, QRS, RR
and heart rate) was evaluated by a 12-lead ECG with triplicate
readouts at scheduled time points, along with changes from
baseline to each scheduled time point.
The TSR-011 CR formulation was evaluated in an open-label
sub-study. Each patient received a single 30-mg CR dose of TSR-
011, administered orally on day 1. The cohort could be expanded
to six patients (3+ 3) if the CR formulation had a desirable PK
profile compared with the IR formulation (i.e. attenuation of
maximum plasma concentration [Cmax] and maintenance of
exposure and lowest plasma trough concentration [Ctrough]). This
sub-study was terminated after evaluation of PK from four
patients, who subsequently rolled over into the main study for
continued treatment.
PK samples, collected before dosing and at 0.5, 1, 2, 4, 8, 12, 18,
24, 32, 44, 48, 72, 96 and 120 h after dosing, were analysed as
above, using the LC–MS/MS method. Nonparametric superposi-
tion modelling (Phoenix WinNonlin software, Pharsight Corpora-
tion) based on the PK of TSR-011 30-mg CR was undertaken to
project a daily CR tablet strength matching the current clinical
exposure of 40 mg three times daily (TID; Q8h).
Statistical analysis
Analyses were descriptive in nature. No formal statistical tests
were performed. Summary tabulations included the number of
observations; mean, standard deviation, median, minimum and
maximum for continuous variables; and number and percentage
per category for categorical data. Percentages were based on the
number of patients with available values, unless specified
otherwise.
The analysis sets included a safety population comprising all
patients who received ≥ 1 dose of study drug; a PK population
comprising all patients who received ≥ 1 dose of study drug and
had measurable drug concentrations; and a clinical activity
population comprising all patients who received ≥ 1 dose of study
drug and had ≥ 1 post-baseline assessment of clinical activity. An
additional analysis was performed on patients who met the
criteria of achieving ≥ 90% study drug compliance during the first
treatment cycle.
RESULTS
Study populations
Over a duration of 4 years, 82 patients were screened and 72 were
enrolled and treated in the phase 1 main study. Sixteen patients
received varying doses of TSR-011, ranging from 30 to 480mg
Q24h. After grade 3 QTc prolongation was observed at doses
above 320mg Q24h, fractional dosing was explored to circumvent
such AEs. A total of 56 patients were enrolled into fractional IR
dose regimen cohorts (30 mg Q12h, n= 6; 60mg Q12h, n= 3;
20mg Q8h, n= 16; 40mg Q8h, n= 31, Fig. S1).
An additional four patients were enrolled in the formulation
sub-study; all were subsequently rolled over into the main study
and treated with 40-mg IR Q8h after completion of cycle 1.
Overall, 65 patients (90.3%) discontinued the study. The most
frequent reason for discontinuation was disease progression (46
patients [63.9%]). The other 19 patients discontinued because of
an AE (n= 3), death (n= 4), physician decision (n= 8), or decline
in clinical status, loss to follow-up, patient inability to attend the
final study visit or withdrawal by the patient (n= 1 each).
Baseline characteristics
Patient demographics and baseline characteristics are summarised
in Table 1. The mean age of enrolled patients in the main study
was 56.9 years (range, 21–87 years). Most patients were female
(56.9%), white (68.1%) and had an ECOG PS of 0 (36.1%) or 1
(59.7%). Of 72 patients enrolled, 56 (77.8%) were ALK inhibitor
treatment naive and 41 (56.9%) were ALK positive.
Safety and tolerability
Overall, patients remained on treatment for a median of 112 days
(range, 4–848 days), and 48.6% of patients remained in the study
for 2–5 cycles, with 28 days per cycle.
A total of 70 patients (97.2%) in the safety population
experienced ≥ 1 treatment-emergent AE (TEAE), as summarised
in Table 2. The most frequently reported TEAEs by class, regardless
of causality, were gastrointestinal disorders (44 patients [61.1%]),
followed by general disorders and administration-site conditions
(fatigue, asthenia, disease progression and peripheral oedema; 36
patients [50.0%]). Individual TEAEs reported in > 15% of patients
included constipation and fatigue (14 patients [19.4%] each);
diarrhoea, vomiting and QTc prolongation (13 patients [18.1%]
each); and asthenia, headache, decreased appetite and anaemia
(11 patients [15.3%] each).
Most TEAEs (64% of events) were grade 1 in severity. However,
grade 3 TEAEs were reported in 37 patients (51.4%; specific grade
3 events reported in > 1 patient are shown in Table 3). One patient
experienced a grade 4 TEAE of anaemia.
Study drug-related TEAEs occurred in 40 patients (55.6%). The
most commonly reported study drug-related TEAEs were QTc
prolongation, constipation, decreased appetite, vomiting and
fatigue (Table 4). One patient (1.4%) experienced a study drug-
related SAE.
Treatment-emergent SAEs occurred in 28 patients (38.9%)
(Table 5). The most frequent SAE among patients with ≥ 1
treatment-emergent SAE was disease progression, which occurred
in six patients (8.3%). All treatment-emergent SAEs were
considered by the investigator as unrelated or unlikely to be
related to the study drug, except for anaemia in one patient that
was considered related to the study drug.
Overall, 12 TEAEs led to study drug discontinuation in 11
patients (15.3%). Of these, ECG QTc prolongation (two patients)
and pneumonitis (one patient) were considered related to the
study drug. Six patients died because of TEAEs, including
disease progression (n= 5) and subarachnoid haemorrhage,
not related to the study drug (n= 1). In addition, one patient
died due to cardiopulmonary failure before receiving the
study drug.
During dose escalation, none of the patients experienced DLTs
in the 30-, 60-, 120- and 240-mg IR Q24h cohorts. Grade 3 QTc
prolongation occurred in two of four patients in the 480-mg Q24h
cohort. Hence, the dose was de-escalated to 320 mg Q24h. One
patient in this cohort experienced grade 3 ECG QTc prolongation
within the DLT period, and an additional patient in this cohort was
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retrospectively determined to have experienced grade 3 QTc
prolongation.
It was hypothesised that QTc prolongation is related to Cmax, so
fractionated dosing was implemented to circumvent QTc prolon-
gation while maintaining the drug trough level. Evaluated cohorts
included 30mg Q12h, 20mg Q8h, 60mg Q12h and 40mg Q8h.
Based on the evaluation of QTc prolongations and PK profiles
(discussed in the following sections), 40-mg IR TID (Q8h) was
determined to be the RP2D.
PK results
Plasma concentration–time profiles (Fig. 1) for both cycle 1/day 1
and cycle 2, day 1/day 29 of TSR-011 were characterised by rapid
absorption, with median time to Cmax (tmax) occurring 2–4 h after a
single oral dose at cycle 1. Following attainment of Cmax, TSR-011
concentrations declined biexponentially. Plasma concentration
profiles were comparable across all cohorts, as well as with repeat
dosing for 29 days. The half-life ranged from 7 to 27 h, with
apparent clearance and apparent volume of distribution of
9.62–46.60 L/h and 188–1620 L, respectively. Systemic exposure
increased supraproportionally, with a 41- and 42-fold increase in
geometric mean Cmax and area under the concentration–time
curve (AUC) from 0 to 24 h, respectively, over the 16-fold increase
in TSR-011 dose (range, 30–480mg).
Table 1. Demographics and baseline characteristics (safety
population)
TSR-011 IR formulation
20mg Q8h
(n= 16)
40mg Q8h
(n= 31)
All patients
(N= 72)
Age, years
Mean (SD) 54.9 (9.64) 51.7 (13.78) 56.9 (13.44)
Median 53.5 51 58
Min–max 36–68 21–77 21–87
Sex, n (%)
Male 8 (50.0) 16 (51.6) 31 (43.1)
Female 8 (50.0) 15 (48.4) 41 (56.9)
Race, n (%)
Asian 5 (31.3) 13 (41.9) 20 (27.8)
Black or African
American
0 1 (3.2) 1 (1.4)
White 10 (62.5) 17 (54.8) 49 (68.1)
Unknown 1 (6.3) 0 2 (2.8)
Smoking history, n (%)
Former 8 (50.0) 15 (48.4) 32 (44.4)
Never 8 (50.0) 16 (51.6) 40 (55.6)
ECOG performance status, n (%)
0 5 (31.3) 13 (41.9) 26 (36.1)
1 10 (62.5) 17 (54.8) 43 (59.7)
2 0 1 (3.2) 2 (2.8)
3 1 (6.3) 0 1 (1.4)
Prior ALK inhibitor treatment, n (%)
Yesa 7 (43.8) 8 (25.8) 16 (22.2)
Crizotinib 6 (37.5) 6 (19.4) 12 (16.7)
Ceritinib 0 3 (9.7) 3 (4.2)
Alectinib 1 (6.3) 1 (3.2) 2 (2.8)
No 9 (56.3) 23 (74.2) 56 (77.8)
ALK-positive mutation status,b n (%)
Yes 10c (62.5) 24d (77.4) 41 (56.9)
No 2 (12.5) 4 (12.9) 11 (15.3)
Not done 4 (25.0) 3 (9.7) 20 (27.8)
TRK-positive mutation status, n (%)
Yes 6 (37.5) 3 (9.7) 11 (15.3)
No 6 (37.5) 28 (90.3) 48 (66.7)
Not done 4 (25.0) 0 13 (18.1)
ALK anaplastic lymphoma kinase, ECOG Eastern Cooperative Oncology
Group, IR immediate release, max maximum, min minimum, Q8h once
every 8 hours, SD standard deviation, TRK tropomyosin-related kinase
aThree patients received two ALK inhibitors
bIncluded gene mutations, amplifications or rearrangements
cThree patients were ALK inhibitor naive
dSeventeen patients were ALK inhibitor naive
Table 2. Overall TEAEs in all patients of the phase 1 main study and
two fractional dose treatment groups
TSR-011 IR formulation
20mg Q8h
(n= 16)
40mg Q8h
(n= 31)
All patients
(N= 72)
Total number of TEAEsa 159 167 621
Number (%) of patients with
Any TEAE 16 (100.0) 29 (93.5) 70 (97.2)
Any serious TEAE 7 (43.8) 12 (38.7) 28 (38.9)
Any study drug-
related TEAE
9 (56.3) 13 (41.9) 40 (55.6)
Any TEAE leading to
treatment
discontinuation
2 (12.5) 5 (16.1) 11 (15.3)
Any AE leading to
deathb
2 (12.5) 2 (6.5) 6 (8.3)
AE adverse event, IR immediate release, Q8h once every 8 hours, TEAE
treatment-emergent adverse event
Note: The total number of AEs counted all TEAEs for patients
aAt each level of patient summarisation, a patient was counted once if the
patient reported one or more event
bNo AEs leading to death were deemed related to treatment
Table 3. Grade 3 treatment-emergent adverse events reported by
more than one patient in the Q8h cohorts compared with the safety
population
Preferred term TSR-011 IR formulation, n (%)
20mg Q8h
(n= 16)
40mg Q8h
(n= 31)
All patients
(N= 72)
Anaemia 2 (12.5) 2 (6.5) 5 (6.9)
Electrocardiogram QTc
prolonged
0 1 (3.2) 4 (5.6)
Asthenia 1 (6.3) 1 (3.2) 3 (4.2)
Dyspnoea 0 0 3 (4.2)
Ascites 1 (6.3) 0 2 (2.8)
Fatigue 1 (6.3) 0 2 (2.8)
Metastases to the central
nervous system
1 (6.3) 1 (3.2) 2 (2.8)
IR immediate release, Q8h once every 8 hours, QTc corrected QT
Note: Adverse events were coded using the Medical Dictionary for
Regulatory Activities, version 18.0. If the severity of an adverse event was
missing, the adverse event was reported as “severe”
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Following daily oral administration of TSR-011 (80–480mg) at
cycle 2/day 1, the median tmax was achieved between 2.00 and
6.00 h, with Cmax ranging from 447.11 to 3327.36 nmol/L. Apparent
clearance and apparent volume of distribution ranged from 9.26
to 29.10 L/h and 206 to 408 L, respectively.
Systemic exposure at steady state increased sub-proportionally
with increasing doses, with a 3.3- and 2.9-fold increase in exposure
for Cmax and AUC from time 0 to the last measurable
concentration, respectively, over the sixfold increase in dose
(range, 80–480 mg). The accumulation ratio, where calculable,
ranged from 0.68 to 5.24.
QTc prolongation, mitigation strategy and RP2D
QTc prolongation was observed during dose escalation and was
the key determinant of the MTD. The relationship between TSR-
011 plasma concentration and change from baseline in QTcF
(ΔQTcF) was explored using linear regression with prediction
intervals (Fig. 1c, solid black lines). All the ΔQTcF data with
matching drug concentration values were used for the analysis.
The correlation was positive and significant (i.e. slope of 0.02358
[red solid line]; 95% confidence interval [CI], 0.01970–0.02747 [red
dotted line]; P < 0.0001), indicating that QTc prolongation was
drug related.
The mean ΔQTcF appeared to be dose dependent (Fig. 1d). All
the available ΔQTcF data from each patient were included in the
analysis. Once-daily (QD) doses at 240mg (n= 3), 320mg (n= 3)
and 480 mg (n= 4) corresponded to a ΔQTcF of > 20ms
(a substantial risk for proarrhythmic disorders, including torsade
de pointes). The mean ΔQTcF for 120mg QD (n= 1) was 19 ms,
with the upper bound of the two-sided 90% CI at 27ms. The data
from one patient in the 30-mg QD cohort were considered to be
outlying. This patient was taking concomitant ondansetron, which
has been associated with QTc prolongation. Therefore, the
observed QTc prolongation may not be related to TSR-011 at this
dose level.
Fractionated dosing was implemented to reduce potential QTc
prolongation. Both twice-daily (BID; Q12h) and TID (Q8h) dosing
Table 5. Treatment-emergent SAEs reported by more than one
patient by system organ class and the preferred term (safety
population)
Preferred term TSR-011 IR formulation
20mg Q8h
(n= 16)
40 mg Q8h
(n= 31)
All patients
(N= 72)
Total number of treatment-emergent
SAEsa
14 16 49
Patients with ≥ 1 treatment-emergent
SAE, n (%)b
7 (43.8) 12 (38.7) 28 (38.9)
Nervous system disorders, n (%) 1 (6.3) 2 (6.5) 8 (11.1)
Mental impairment, n (%) 1 (6.3) 0 2 (2.8)
Seizure 1 (6.3) 1 (3.2) 2 (2.8)
Subarachnoid haemorrhage 0 1 (3.2) 1 (1.4)
General disorders and
administration-site conditions, n (%)
2 (12.5) 2 (6.5) 7 (9.7)
Disease progression 2 (12.5) 2 (6.5) 6 (8.3)
Asthenia 1 (6.3) 0 1 (1.4)
Gastrointestinal disorders, n (%) 1 (6.3) 1 (3.2) 5 (6.9)
Abdominal pain 0 1 (3.2) 1 (1.4)
Gastric haemorrhage 1 (6.3) 0 1 (1.4)
Infections and infestations, n (%) 1 (6.3) 4 (12.9) 5 (6.9)
Gastric ulcer helicobacter 0 1 (3.2) 1 (1.4)
Infection 0 1 (3.2) 1 (1.4)
Lower respiratory tract infection 0 1 (3.2) 1 (1.4)
Mastoiditis 1 (6.3) 0 1 (1.4)
Pneumonia 0 1 (3.2) 1 (1.4)
Respiratory, thoracic and mediastinal
disorders, n (%)
0 1 (3.2) 4 (5.6)
Dyspnoea 0 0 3 (4.2)
Pleural effusion 0 1 (3.2) 1 (1.4)
Neoplasms benign, malignant and
unspecified (including cysts and
polyps), n (%)
2 (12.5) 1 (3.2) 3 (4.2)
Metastases to the central nervous
system, n (%)
1 (6.3) 1 (3.2) 2 (2.8)
Basal cell carcinoma 1 (6.3) 0 1 (1.4)
Blood and lymphatic system
disorders, n (%)
0 2 (6.5) 2 (2.8)
Anaemia 0 2 (6.5) 2 (2.8)
Cardiac disorders 0 1 (3.2) 1 (1.4)
Pericardial effusion 0 1 (3.2) 1 (1.4)
Hepatobiliary disorders, n (%) 1 (6.3) 0 1 (1.4)
Portal vein thrombosis 1 (6.3) 0 1 (1.4)
Metabolism and nutrition disorders,
n (%)
1 (6.3) 0 1 (1.4)
Dehydration 1 (6.3) 0 1 (1.4)
Musculoskeletal and connective
tissue disorders, n (%)
1 (6.3) 0 1 (1.4)
Bone pain 1 (6.3) 0 1 (1.4)
Vascular disorders, n (%) 1 (6.3) 0 1 (1.4)
Deep-vein thrombosis 1 (6.3) 0 1 (1.4)
AE adverse event, IR immediate release, Q8h once every 8 hours, SAE
serious adverse event
Note: AEs were coded using the Medical Dictionary for Regulatory Activities,
version 18.0
aThe total number of treatment-emergent SAEs counts all treatment-
emergent SAEs for patients
bAt each level of patient summarisation, a patient was counted once if the
patient reported one or more event
Table 4. Drug-related treatment-emergent adverse events reported
by more than one patient in the Q8h cohorts compared with the
safety population
Preferred term TSR-011 IR formulation, n (%)
20mg Q8h
(n= 16)
40mg Q8h
(n= 31)
All patients
(N= 72)
Electrocardiogram QTc
prolonged
1 (6.3) 3 (9.7) 12 (16.7)
Constipation 2 (12.5) 2 (6.5) 5 (6.9)
Decreased appetite 1 (6.3) 0 4 (5.6)
Vomiting 2 (12.5) 1 (3.2) 4 (5.6)
Fatigue 1 (6.3) 0 4 (5.6)
Diarrhoea 1 (6.3) 0 3 (4.2)
Dysgeusia 0 0 3 (4.2)
Nausea 0 1 (3.2) 3 (4.2)
Peripheral oedema 0 1 (3.2) 3 (4.2)
Headache 0 0 3 (4.2)
Abnormal dreams 1 (6.3) 0 2 (2.8)
Anaemia 0 1 (3.2) 2 (2.8)
Asthenia 1 (6.3) 0 2 (2.8)
Dysaesthesia 1 (6.3) 0 2 (2.8)
Hot flush 1 (6.3) 0 2 (2.8)
Insomnia 0 2 (6.5) 2 (2.8)
Myalgia 0 0 2 (2.8)
Rash 0 1 (3.2) 2 (2.8)
Increased transaminases 0 0 2 (2.8)
IR immediate release, Q8h once every 8 hours, QTc corrected QT interval
Note: At each level of patient summarisation, a patient was counted once if
the patient reported one or more event. Adverse events were coded using
the Medical Dictionary for Regulatory Activities, version 18.0
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regimens were explored at cumulative daily doses of 60 and 120
mg (Fig. 1d). This strategy maintained mean ΔQTcF below 20ms
for all four dose regimens. The highest mean ΔQTcF of 11 ms (90%
CI, 9.75–12.00 ms) was observed in the 40-mg TID cohort (n= 27).
While no specific guidance exists, it is generally considered
acceptable to conclude that a change in QTc from baseline is not
clinically meaningful, if the upper bound of the two-sided 90% CI
for the ΔQTcF is < 20ms. At 40-mg TID dosing, there was one
observed grade 3 TEAE of QTc prolongation. The dose of 40 mg
TID (Q8h) was determined to be the RP2D; dose escalation was
stopped.
CR formulation
Rationale for a switch from IR to CR. Fractionated dosing (Q8h)
was successful in minimising the ratio of Cmax to Ctrough while
maintaining the required drug trough level. At the 120-mg QD
dose (day 29 of steady state, n= 1), this ratio was ~2.00. It was
reduced to ~1.42 (day 29 of steady state, n= 25) with the 40-mg
TID (Q8h) dose, which was equivalent to a 120-mg cumulative
daily dose. At this dosage and regimen, the overall steady-state PK
profile (day 29, n= 22–25) exhibited high interpatient variability,
with percent coefficients of variation ranging from 108 to 132%
and a mean Cmax and Ctrough of 528.41 and 351.38 nmol/L,
respectively. The PK profiles were also evaluated using the
fluctuation index, defined as (Cmax–Ctrough)/Cavg, and swing
percentage, defined as (Cmax–Ctrough)/Ctrough × 100, with ranges
of 0.25–1.60 and 28.8–295.0%, respectively. The CR formulation
was under development to mimic the PK profile of 40 mg TID, with
the potential to generate a more continuous effect through
compliance with the daily dosage routine and maintenance of
therapeutic plasma concentrations. Less fluctuation and swing are
desirable in a CR formulation through reduced intrapatient
variability. The criteria set for the new formulation were such that
the mean Cmax/Ctrough ratio should be maintained within 2.00,
with a Ctrough of about 351.38 nmol/L. No observed concentration
should be higher than 2599.50 nmol/L, which was the highest
concentration observed in the 40-mg IR TID cohort.
PK of CR formulation. A CR formulation was subsequently
developed to mimic the PK profile of the 40-mg TID (Q8h) dose,
including the mean Ctrough. PK parameters were measured in a
cohort of four patients who received a 30-mg CR formulation.
The mean Cmax was 37.95 nmol/L, and tmax occurred ~4 h after
dosing. Based on nonparametric superposition modelling,
consistent with fractionated dosing, the ratio of mean Cmax to
mean Ctrough was maintained at about 1.65 of steady state with
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Fig. 1 Mean ± SEM plasma concentration–time profiles (semi-log) of TSR-011 following single oral daily doses in patients with cancer. a Cycle
1/day 1. b Cycle 2/day 1. Summary of ΔQTcF by plasma concentration and dose. c PK concentration–response (PK-QT) relationship from all
dose groups (30mg QD, 60mg QD, 80mg QD, 120mg QD, 240mg QD, 320mg QD, 480mg QD, 30mg Q12h, 20mg Q8h, 60mg Q12h, 40mg
Q8h and 30mg QD controlled release). d Plot of dose and regimen versus mean ΔQTcF (ms) from baseline with 90% CI. ΔQTcF change in
Fridericia-corrected QT interval, CI confidence interval, Conc concentration, IR immediate release, PK pharmacokinetics, Q8h once every
8 hours, Q12h once every 12 hours, QD once daily, SEM standard error of the mean
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daily dosing. In addition, based on the 30-mg CR prototype, a
240-mg CR daily dose was projected to match the clinical
exposure of 40 mg TID (Q8h). The trough level for the 240-mg CR
prototype was about 415.92 nmol/L, which matches the trough
of 40 mg TID (Q8h) at a mean of 351.38 nmol/L. The mean Cmax
was projected to be < 693.20 nmol/L. Based on the linear
regression (Fig. 1c), at 693.20 nmol/L, the mean ΔQTcF with
95% CI ranged from 10.6 to 16.7 ms, which is within the
manageable risk of QTc prolongation.
Efficacy
While tumour response data were collected from 66 patients,
here, we present response data only for patients with ALK-
positive tumour samples (n= 22) receiving the RP2D (40 mg
Q8h). Fourteen of these patients were ALK inhibitor naive, and
eight had been previously treated with an ALK inhibitor. No ALK-
positive patient had a complete response; seven patients had a
partial response (six confirmed, one unconfirmed) and 14 had
stable disease. Among ALK inhibitor-naive patients, six had
partial responses (five confirmed, one unconfirmed) and eight
had stable disease (Table S1). The median duration of treatment
was 112 days (range, 4–848 days), and 47% of patients remained
in the study for 2–5 cycles. Three ALK-positive patients are
continuing in the study and receiving the study drug as of the
time of the study report. A patient with a neuroblastoma
harbouring an ALK mutation (R1275Q) did not respond to TSR-
011 treatment.
DISCUSSION
The PK and safety of TSR-011 were studied in this sequential,
open-label, nonrandomised, dose-escalation, phase 1 clinical trial
at doses ranging from 20 to 480mg administered to patients with
relapsed or refractory locally advanced or metastatic cancer. The
320- and 480-mg Q24h doses exceeded the MTD. Patients in these
cohorts experienced grade 3 ECG QTc prolongation. Fractional
dosing in subsequent cohorts resulted in an RP2D of 40 mg
TID (Q8h).
Safety data show that the RP2D was generally well tolerated,
with an acceptable and manageable AE profile. Compared with
AEs of grade ≥ 3 severity reported with the use of alectinib or
brigatinib,17,18 no grade ≥ 3 pneumonitis or hypoxia was observed
in patients treated with TSR-011 (40 mg TID). Longer-term
treatment of patients at this dosage suggested that most could
continue treatment with dose interruptions or dose reductions to
manage TEAEs.
At the 40-mg TID (Q8h) RP2D (n= 27, QTc-evaluable patients),
the frequency of drug-related QTc prolongation was lower
compared with the overall safety population (9.7% vs 16.7%,
respectively). One in 27 patients (3.7%) had a ΔQTc of > 60ms and
a QTc > 500ms (a grade 3 event). Clinical trials of ceritinib showed
that, among 919 patients, 6% had a ΔQTc of > 60ms and 1.3% had
a QTc > 500 ms.19 In clinical trials of alectinib and brigatinib, QTc
was not prolonged to any clinically relevant extent.17,18
PK analyses showed that after single-dose administration of
TSR-011, systemic exposure Cmax and AUC values increased
supraproportionally over the 30- to 480-mg dose range. Profiling
of the CYPs responsible for metabolism of TSR-011 was
conducted, using a panel of recombinant CYP enzymes and liver
microsomes. The results indicated that CYP3A4 is responsible for
the majority of CYP-dependent metabolism of TSR-011, with
minor amounts of metabolism by other enzymes, including
CYP2D6, CYP2C9, and CYP1A. Meanwhile, TSR-011 inhibited
CYP3A4 and CYP2D6 in human liver microsomes, with an IC50 of
23.3 and 32.9 µM, respectively, which may provide a rationale for
the supraproportional systemic exposure observed after adminis-
tration of a single dose. After repeated dosing, systemic exposure
at steady state increased in a sub-proportional manner over the
dose range of 80–480 mg. TSR-011 is a substrate of efflux
transporters with a Papp(B–A)/(A–B) ratio of 7.7. It is speculated
that with repeated dosing, TSR-011 may induce the transporters as
well as CYP enzymes at higher doses. Overall, high interpatient
variability in the Cmax and AUC PK parameters was observed in
these cohorts.
To date, five ALK inhibitors (crizotinib, ceritinib, alectinib,
brigatinib and lorlatinib) have been approved by the US Food
and Drug Administration for treatment of advanced NSCLC
harbouring ALK aberrations.5 Approved ALK inhibitor formulations
have less frequent dosing schedules than TSR-011 at Q8h. For
example, alectinib and crizotinib are dosed BID and ceritinib is
dosed QD.19 Therefore, the TSR-011 CR formulation was an
attractive line of inquiry. In the formulation sub-study, after a
single 30-mg CR dose of TSR-011, Cmax and AUC values were lower
than those observed with a single 30-mg IR dose of TSR-011. There
was high interpatient variability in the Cmax and AUC parameters.
Nonparametric superposition projected that 240 mg of this CR
would have Ctrough of about 415.92 nmol/L, which matches the
40mg IR TID cohort, with a Cmax of about 693.20 nmol/L, at which
QTc prolongation is manageable.
At the RP2D, TSR-011 demonstrated clinical activity in the ALK-
positive NSCLC subgroup that included both ALK inhibitor-naive
patients and those previously treated with an ALK inhibitor. A
higher response rate was observed in ALK inhibitor-naive patients
(partial response rate, 42.9% vs 12.5%, respectively). Stable disease
occurred in eight ALK inhibitor-naive patients (57.1%) and six
patients previously treated with an ALK inhibitor (75.0%). The
observed efficacy of TSR-011 at the RP2D appears to be
significantly less than that of other ALK inhibitors, which have
shown an objective response rate of > 70% in a similar population.
Similarly, an objective response rate of 12.5% is notably lower in
the ALK pre-treated setting than what has been reported with all
next-generation ALK inhibitors post crizotinib (55%, ceritinib;
38–48%, alectinib; 45–54%, brigatinib; 48%, lorlatinib). This was
due to a suboptimal RP2D, which was limited by QTc prolonga-
tion. In preclinical studies, mice treated with an oral dose of TSR-
011 60mg/kg showed complete ALK inhibition in Karpas-299
tumours at 8 h, with a plasma concentration of 698.00 nmol/L. Oral
daily dosing of 60 mg/kg resulted in > 80% tumour growth
inhibition, with an overall 24-h exposure of 15,500 ng×h/mL. A
similar drug exposure for humans would require a daily dose
ranging from 150 to 720 mg, based on the apparent clearance of
9.62–46.60 L/h. Exposure of the RP2D at 40 mg TID (Q8h) (Fig. 1b)
was lower than that of 120mg IR QD. The high interpatient
variability of PK was not favourable for the further development of
the compound.
In conclusion, dose escalation of TSR-011 in patients with
relapsed or refractory cancers established the RP2D of 40 mg TID
(Q8h). QTc prolongation was a DLT with Q24h dosing at or above
320mg. At the RP2D, TSR-011 had a favourable safety profile
compared with most approved ALK inhibitors. Based on the
competitive ALK inhibitor landscape and DLT of QTc prolongation,
the development of TSR-011 has been discontinued.
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